OpenURL Connection Search

Select item for more details and to access through your institution.

Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
Published in:
European Review for Medical & Pharmacological Sciences, 2010, v. 14, n. 6, p. 347
By:
- BODEI, L.;
- PEPE, G.;
- PAGANELLI, G.
Publication type:
Article
Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
Published in:
European Review for Medical & Pharmacological Sciences, 2010, v. 14, n. 4, p. 347
By:
- BODEI, L.;
- PEPE, G.;
- PAGANELLI, G.
Publication type:
Article
Efficacy of Peptide Receptor Radionuclide Therapy Treatment with 177Ludotatate in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors.
Published in:
Neuroendocrinology, 2012, v. 96, p. 57
By:
- Sansovini, M.;
- Severi, S.;
- Ambrosetti, A.;
- Monti, M.;
- Nanni, O.;
- Bodei, L.;
- Garaboldi, L.;
- Bartolomei, M.;
- Sarnelli, A.;
- Paganelli, G.
Publication type:
Article
The clinical utility of circulating neuroendocrine gene transcript analysis in well-differentiated paragangliomas and pheochromocytomas.
Published in:
European Journal of Endocrinology, 2017, v. 176, n. 2, p. 143, doi. 10.1530/EJE-16-0727
By:
- Pęczkowska, M.;
- Cwikla, J.;
- Kidd, M.;
- Lewczuk, A.;
- Kolasinska-Ćwikła, A.;
- Niec, D.;
- Michałowska, I.;
- Prejbisz, A.;
- Januszewicz, A.;
- Chiarelli, J.;
- Bodei, L.;
- Modlin, I.
Publication type:
Article
Is CD20 the only target available for radionuclide therapy in lymphoproliferative disorders?
Published in:
2005
By:
- Agazzi, A.;
- Rocca, P.;
- Laszlo, D.;
- Bodei, L.;
- Grana, C.;
- Martinelli, G.;
- Paganelli, G.
Publication type:
Letter
Pregnant with metastatic neuroendocrine tumour of the ovary: what now?
Published in:
Ecancermedicalscience, 2012, v. 6, p. 1, doi. 10.3332/ecancer.2012.240
By:
- Pistilli, B.;
- Grana, C. M.;
- Fazio, N.;
- Cavaliere, A.;
- Ferrari, M. E.;
- Bodei, L.;
- Baio, S. M.;
- Scambia, G.;
- Paganelli, G.;
- Peccatori, F. A.
Publication type:
Article
Institutional guidelines and ongoing studies in management of liver tumours: the experience of the European Institute of Oncology.
Published in:
Ecancermedicalscience, 2008, v. 2, p. 1, doi. 10.3332/ecancer.2008.64
By:
- Biffi, R.;
- Orsi, F.;
- Zampino, M. G.;
- Chiappa, A.;
- Fazio, N.;
- De Braud, F.;
- Bonomo, G.;
- Monfardini, L.;
- Vigna, P. D.;
- Luca, F.;
- Bodei, L.;
- Bartolomei, M.;
- Catalano, G.;
- Leonardi, M. C.;
- Ferrari, M.;
- Andreoni, B.;
- Goldhirsch, A.;
- Paganelli, G.;
- Orecchia, R.
Publication type:
Article
Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.
Published in:
European Journal of Nuclear Medicine & Molecular Imaging, 2016, v. 43, n. 5, p. 839, doi. 10.1007/s00259-015-3250-z
By:
- Bodei, L.;
- Kidd, M.;
- Modlin, I.;
- Severi, S.;
- Drozdov, I.;
- Nicolini, S.;
- Kwekkeboom, D.;
- Krenning, E.;
- Baum, R.;
- Paganelli, G.
Publication type:
Article
Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks.
Published in:
2015
By:
- Pfestroff, A.;
- Luster, M.;
- Jilg, C.;
- Olbert, P.;
- Ohlmann, C.;
- Lassmann, M.;
- Maecke, H.;
- Ezziddin, S.;
- Bodei, L.
Publication type:
Editorial
Gene transcript analysis blood values correlate with Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.
Published in:
European Journal of Nuclear Medicine & Molecular Imaging, 2015, v. 42, n. 9, p. 1341, doi. 10.1007/s00259-015-3075-9
By:
- Bodei, L.;
- Kidd, M.;
- Modlin, I.;
- Prasad, V.;
- Severi, S.;
- Ambrosini, V.;
- Kwekkeboom, D.;
- Krenning, E.;
- Baum, R.;
- Paganelli, G.;
- Drozdov, I.
Publication type:
Article
Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.
Published in:
2014
By:
- Bodei, L.;
- Mueller-Brand, J.;
- Baum, R.;
- Pavel, M.;
- Hörsch, D.;
- O'Dorisio, M.;
- O'Dorisio, T.;
- Howe, J.;
- Cremonesi, M.;
- Kwekkeboom, D.;
- Zaknun, J.
Publication type:
Correction Notice
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.
Published in:
European Journal of Nuclear Medicine & Molecular Imaging, 2013, v. 40, n. 5, p. 800, doi. 10.1007/s00259-012-2330-6
By:
- Zaknun, John;
- Bodei, L.;
- Mueller-Brand, J.;
- Pavel, M.;
- Baum, R.;
- Hörsch, D.;
- O'Dorisio, M.;
- O'Dorisiol, T.;
- Howe, J.;
- Cremonesi, M.;
- Kwekkeboom, D.
Publication type:
Article
Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”.
Published in:
European Journal of Nuclear Medicine & Molecular Imaging, 2007, v. 34, n. 5, p. 772, doi. 10.1007/s00259-006-0338-5
By:
- Brans, B.;
- Bodei, L.;
- Giammarile, F.;
- Linden, O.;
- Luster, M.;
- Oyen, W. J. G.;
- Tennvall, J.
Publication type:
Article
90Y-DOTA- D-Phe1-Try3- octreotide in therapy of neuroendocrine malignancies.
Published in:
Biopolymers, 2002, v. 66, n. 6, p. 393, doi. 10.1002/bip.10349
By:
- Paganelli, G.;
- Bodei, L.;
- Handkiewicz Junak, D.;
- Rocca, P.;
- Papi, S.;
- Lopera Sierra, M.;
- Gatti, M.;
- Chinol, M.;
- Bartolomei, M.;
- Fiorenza, M.;
- Grana, C.
Publication type:
Article
Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group.
Published in:
2003
By:
- De Pas, T;
- Bodei, L;
- Pelosi, G;
- de Braud, F;
- Villa, G;
- Capanna, R;
- Paganelli, G;
- Italian Sarcoma Group
Publication type:
journal article
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.
Published in:
European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 5, p. 1682, doi. 10.1007/s00259-021-05600-z
By:
- Weber, M.;
- Lam, M.;
- Chiesa, C.;
- Konijnenberg, M.;
- Cremonesi, M.;
- Flamen, P.;
- Gnesin, S.;
- Bodei, L.;
- Kracmerova, T.;
- Luster, M.;
- Garin, E.;
- Herrmann, K.
Publication type:
Article
Kidney dosimetry in (177)lu and (90)y Peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors.
Published in:
2013
By:
- Guerriero, F;
- Ferrari, M E;
- Botta, F;
- Fioroni, F;
- Grassi, E;
- Versari, A;
- Sarnelli, A;
- Pacilio, M;
- Amato, E;
- Strigari, L;
- Bodei, L;
- Paganelli, G;
- Iori, M;
- Pedroli, G;
- Cremonesi, M
Publication type:
Journal Article
Kidney Dosimetry in 177Lu and 90Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors.
Published in:
BioMed Research International, 2013, v. 2013, p. 1, doi. 10.1155/2013/935351
By:
- Guerriero, F.;
- Ferrari, M. E.;
- Botta, F.;
- Fioroni, F.;
- Grassi, E.;
- Versari, A.;
- Sarnelli, A.;
- Pacilio, M.;
- Amato, E.;
- Strigari, L.;
- Bodei, L.;
- Paganelli, G.;
- Iori, M.;
- Pedroli, G.;
- Cremonesi, M.
Publication type:
Article
The Clinical Utility of a Novel Blood-Based Multi-Transcriptome Assay for the Diagnosis of Neuroendocrine Tumors of the Gastrointestinal Tract.
Published in:
American Journal of Gastroenterology (Springer Nature), 2015, v. 110, n. 8, p. 1223, doi. 10.1038/ajg.2015.160
By:
- Modlin, I M;
- Kidd, M;
- Bodei, L;
- Drozdov, I;
- Aslanian, H
Publication type:
Article

Found: 19

Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.

Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.

Efficacy of Peptide Receptor Radionuclide Therapy Treatment with 177Ludotatate in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors.

The clinical utility of circulating neuroendocrine gene transcript analysis in well-differentiated paragangliomas and pheochromocytomas.

Is CD20 the only target available for radionuclide therapy in lymphoproliferative disorders?

Pregnant with metastatic neuroendocrine tumour of the ovary: what now?

Institutional guidelines and ongoing studies in management of liver tumours: the experience of the European Institute of Oncology.

Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.

Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks.

Gene transcript analysis blood values correlate with Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.

Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.

Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”.

<sup>90</sup>Y-DOTA- D-Phe<sup>1</sup>-Try<sup>3</sup>- octreotide in therapy of neuroendocrine malignancies.

Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group.

EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.

Kidney dosimetry in (177)lu and (90)y Peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors.

Kidney Dosimetry in <sup>177</sup>Lu and <sup>90</sup>Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors.

The Clinical Utility of a Novel Blood-Based Multi-Transcriptome Assay for the Diagnosis of Neuroendocrine Tumors of the Gastrointestinal Tract.